February 24, 2021 5:35pm

After a bounce and more than an ounce of upside

Pre-open indication results: 7 HITs and 2 MISS

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

The Dow closed UP +424.51 points (+1.35%); the S&P closed UP +44.06 points (+1.14%) while the Nasdaq closed UP +132.77 points (+0.99%)


Henry’omics - more than a snapshot of today’s sector movements:

Indexes staged another comeback on Wednesday as investors piled into cell and gene names; sensitive to volatility, while looking past the risk of inflation and rising interest rates.

The Nasdaq index, which traded as much as 1.3% lower earlier in the session, regained its footing by early afternoon and closed up.

Reiterating, “the FDA’s staff endorsed Johnson & Johnson’s (JNJ) single-shot Covid-19 vaccine for emergency use, bringing in a third vaccine to the U.S.”


Data Docket: “In Wednesday’s testimony in front of the House of Representatives Financial Services Committee, Powell added that inflation could be volatile as the economy reopens and there is increased demand. But he does not expect inflation to run hot and said the central bank has the tools to fight it if it should.” <CNBC>


RegMed Investors’ (RMi) pre-open: “a bounce, a pounce or just an ounce of upside needed as beat-down shares still have today’s Q4 and FY20 earnings’ releases to deal with” …  https://www.regmedinvestors.com/articles/11784


Pre-open indication results:  7 HITs < SELL: Biostage (BSTG -$0.00 with 4,062 shares traded); BUY: Applied Genetic Technologies (AGTC +$0.24), bluebird bio (BLUE +$0.30), Pluristem (PSTI +$0.18), Intellia Therapeutics (NTLA +$0.15); Falling Knife: Sage Therapeutics (SAGE +$5.40)> SELL: Solid Biosciences (SLDB -$0.53)> and 2 MISS < CRISPR Therapeutics (CRSP -$1.78), Mesoblast (MESO -$0.58),


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Wednesday opened positive at 20/12, 2 flat and 1 acquired, stayed positive at the mid-day to 31/1, 3 flat and 1 acquired, closing positive at 7/25, 2 flats and 1 acquired;


There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

  • Sage Therapeutics (SAGE), Ultragenyx (RARE), Vericel (VCEL), uniQure NV (QURE), Global Blood Therapeutics (GBT) to name 5 of the 25 inclining of the 35 covered

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO), Solid Bioscience (SLDB), Fate Therapeutics (FATE), Homology Medicine (FIXX), Adverum Biotechnologies (ADVM) to name 7 of the 7 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 5 of the 25-upside having higher than the 3-month average volume with the increased volume of 2 of 7-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 25-upside were +0.24% (NTLA) to +13.37% (CLBS) while the 7-downside ranges from -0.22% (FATE) to -5.74% (MESO);


Wednesday’s (10 of 25) incline

  • Sage Therapeutics (SAGE +$4.80 and Tuesday’s -$0.85);
  • Ultragenyx (RARE +$2.51 after Tuesday’s -$4.47 and Monday’s -$3.45);
  • Vericel (VCEL +$2.08 after Tuesday’s -$1.07 and Monday’s -$2.96);
  • uniQure NV (QURE +$1.29);
  • Global Blood Therapeutics (GBT +$1.16);
  • Chinook Therapeutics (KDNY +$1.08);
  • Regenxbio (RGNX +$0.90 after Tuesday’s -$0.62 and Monday’s -$2.52);
  • AxoGen (AXGN +$0.76 after Tuesday’s +$0.21);
  • Editas Medicine (EDIT +$0.56 after Tuesday’s -$3.26 and Monday’s -$4.07);
  • Cellectis SA (CLLS +$0.53 after Tuesday’s -$1.32);

Wednesday’s (7 of 7) decliners:

  • CRISPR Therapeutics (CRSP -$1.78 after Tuesday’s -$2.59 and Monday’s -$10.42);
  • Alnylam Pharmaceuticals (ALNY -$1.62 after Tuesday’s +$5.14 and Monday’s -$4.73);
  • Mesoblast (MESO -$0.58);
  • Solid Biosciences (SLDB -$0.53 after Tuesday’s +$2.87);
  • Fate Therapeutics (FATE -$0.21 after Tuesday’s -$5.48 and Monday’s -$9.22);
  • Homology Medicine (FIXX -$0.18);
  • Adverum Biotechnologies (ADVM -$0.04 after Tuesday’s +$0.83);

Closing 2 – Biostage (BSTG), ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • The FDA endorsed Johnson & Johnson’s (JNJ) single-shot Covid-19 vaccine for emergency use, bringing in a third (3rd) vaccine to the U.S.

Infection cases <Million>: never to forget …

  • Wednesday 28.26 M cases,
  • Wednesday’s death rate totaled 502,856 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed up +0.97% and XBI closed up +1.51%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -1.77 points or -7.66% at 21.34

Upside volume: low

  • Wednesday: 5 out of the 25-upside had higher than the 3-month average volume;

Downside volume: low

  • Wednesday: 2 out of the 7-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Wednesday’s percentage (%) of the 25-upside were +0.24% (NTLA) to +13.37% (CLBS) while the 7-downside ranges from -0.22% (FATE) to -5.74% (MESO);


February, the 2nd month of Q1 … the final week:

Wednesday closed positive with 25 advancers, 7 decliners, 2 flat and 1 acquired


The BOTTOM LINE: I felt it was in the “cards” for a bounce, volatility is always expected; the deeper the preceding dive, the obvious way back is usually expected.

It’s STILL all about, the “bouncing ball” of sector momentum …

As I stated this a.m., “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.